Scribd Logo
Upload

Welcome to Scribd!

  • 2019 - TTT of Concomintant AD With PAD,, Results of Registry II,, Inohara Et Al

    Uploaded by

    Alaa
    9 views6 pages
    The study examined 6,203 participants with new-onset atrial fibrillation (AF), finding that 31% had concomitant vascular disease. Among those with both AF and vascular disease, 23.4% were treated with direct-acting oral anticoagulants (DOACs) while 62.2% received warfarin. The rates of major adverse cardiovascular and neurological events were highest in those with both vascular disease and not receiving anticoagulation therapy, while DOAC treatment was associated with the lowest rates. Bleeding rates were also highest in those with vascular disease taking warfarin or antiplatelet drugs, with no evidence that antiplatelet use improved outcomes.

    Original Description:

    Concomintant AD With PAD,,

    Original Title

    2019 - Ttt of Concomintant AD With PAD,, Results of Registry II,, Inohara Et Al

    Copyright

    © © All Rights Reserved

    Available Formats

    PPTX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    The study examined 6,203 participants with new-onset atrial fibrillation (AF), finding that 31% had concomitant vascular disease. Among those with both AF and vascular disease, 23.4% were treated with direct-acting oral anticoagulants (DOACs) while 62.2% received warfarin. The rates of major adverse cardiovascular and neurological events were highest in those with both vascular disease and not receiving anticoagulation therapy, while DOAC treatment was associated with the lowest rates. Bleeding rates were also highest in those with vascular disease taking warfarin or antiplatelet drugs, with no evidence that antiplatelet use improved outcomes.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    9 views6 pages

    2019 - TTT of Concomintant AD With PAD,, Results of Registry II,, Inohara Et Al

    Uploaded by

    Alaa
    The study examined 6,203 participants with new-onset atrial fibrillation (AF), finding that 31% had concomitant vascular disease. Among those with both AF and vascular disease, 23.4% were treated with direct-acting oral anticoagulants (DOACs) while 62.2% received warfarin. The rates of major adverse cardiovascular and neurological events were highest in those with both vascular disease and not receiving anticoagulation therapy, while DOAC treatment was associated with the lowest rates. Bleeding rates were also highest in those with vascular disease taking warfarin or antiplatelet drugs, with no evidence that antiplatelet use improved outcomes.

    Copyright:

    © All Rights Reserved
    Download as PPTX, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 6

    Inohara et al (2019). Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease.

    American Heart Journal. doi:10.1016/j.ahj.2019.04.007


    31%

    of 6203 participants with “new-


    onset AF” had vascular disease.

    Adapted from: Inohara et al (2019). Treatment of atrial fibrillation with concomitant coronary or peripheral
    artery disease. American Heart Journal. doi:10.1016/j.ahj.2019.04.007
    Type of OAC used in patients with
    AF + Vascular Disease

    23.4%
    62.2%

    DOACs Warfarin ?

    Adapted from: Inohara et al (2019). Treatment of atrial fibrillation with concomitant coronary or peripheral
    artery disease. American Heart Journal. doi:10.1016/j.ahj.2019.04.007
    Major Adverse Cardiovascular & Neurological
    Events Rates in Different Groups
    2

    1.8

    1.6

    1.4

    1.2

    0.8

    0.6

    0.4

    0.2

    0
    MACNE
    No-Vasc Vasc Series3 Vasc-VKA
    Vasc-DOACs Series6 No-Plt Plt

    Adapted from: Inohara et al (2019). Treatment of atrial fibrillation with concomitant coronary or peripheral
    artery disease. American Heart Journal. doi:10.1016/j.ahj.2019.04.007
    Bleeding Rates in Different Groups
    2.5

    1.5

    0.5

    0
    Bleeding
    No-Vasc Vasc Series3 Vasc-VKA
    Vasc-DOACs Series6 No-Plt Plt

    Adapted from: Inohara et al (2019). Treatment of atrial fibrillation with concomitant coronary or peripheral
    artery disease. American Heart Journal. doi:10.1016/j.ahj.2019.04.007
    Concomitant Use of Antiplatelets
    increased the Bleeding without
    Evidences of Improved Outcome

    Adapted from: Inohara et al (2019). Treatment of atrial fibrillation with concomitant coronary or peripheral
    artery disease. American Heart Journal. doi:10.1016/j.ahj.2019.04.007

    You might also like